Home Data Calendar Blog

DTIL

Tables

		2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31
Weighted Average Number Of Diluted Shares Outstanding		114.10	111.30	NA	110.85	67.95	61.03	NA	59.66	59.84	NA	NA	NA	51.91	NA	NA	NA	NA	NA	NA	NA	NA	NA
Weighted Average Number Of Shares Outstanding Basic		114.10	111.30	NA	110.85	67.95	61.03	NA	59.66	57.74	NA	NA	NA	51.91	NA	NA	NA	NA	NA	NA	NA	NA	NA
Weighted Average Number Of Share Outstanding Basic And Diluted		NA	NA	NA	NA	NA	61.03	NA	59.66	NA	56.63	NA	52.35	51.91	51.31	NA	50.62	50.04	15.97	NA	15.82	15.73	15.70
Earnings Per Share Basic		-0.10	-0.23	-0.23	-0.22	-0.46	-0.46	-0.38	-0.19	0.38	NA	NA	NA	-0.63	NA	NA	NA	NA	NA	NA	NA	NA	NA
Earnings Per Share Diluted		-0.10	-0.23	-0.23	-0.22	-0.46	-0.46	-0.38	-0.19	0.36	NA	NA	NA	-0.63	NA	NA	NA	NA	NA	NA	NA	NA	NA
Earnings Per Share Basic And Diluted		NA	NA	NA	NA	NA	-0.46	-0.38	-0.19	NA	-0.33	-0.44	-0.50	-0.63	-0.52	-0.36	-0.41	-0.39	-1.99	-0.98	-0.62	-0.75	-0.57

		2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31
Revenue From Contract With Customer Excluding Assessed Tax		19.79	8.78	10.60	7.36	3.82	3.32	6.34	24.04	68.81	16.35	8.85	7.36	1.08	7.00	6.52	4.87	5.39	5.46	4.94	2.54	1.87	1.53
Revenues		19.79	8.78	10.60	7.36	3.82	3.32	6.34	24.04	68.81	16.35	8.85	7.36	1.08	7.00	6.52	4.87	5.39	5.46	4.94	2.54	1.87	1.53
Operating Expenses		31.78	33.24	31.09	30.29	33.42	30.66	37.09	35.58	47.17	35.09	32.33	33.41	33.89	34.49	28.38	26.84	29.26	24.96	21.05	12.99	14.00	10.76
Research And Development Expense		21.95	22.16	21.07	19.96	22.94	19.97	26.47	25.94	37.23	25.59	23.13	24.87	25.18	24.88	19.90	19.79	22.76	19.96	16.40	9.74	10.87	8.12
General And Administrative Expense		9.83	11.09	10.02	10.33	10.48	10.69	10.62	9.64	9.94	9.50	9.20	8.53	8.70	9.62	8.48	7.05	6.50	5.00	4.65	3.25	3.13	2.65
Operating Income Loss		-11.99	-24.46	-20.49	-22.93	-29.60	-27.35	-30.75	-11.54	21.63	-18.74	-23.48	-26.04	-32.81	-27.50	-21.86	-21.98	-23.87	-19.49	-16.11	-10.45	-12.12	-9.23
Interest Expense		0.55	0.52	0.49	0.41	0.18	0.04	0.05	0.06	0.02	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Interest Paid Net		0.50	0.46	0.40	0.32	0.07	0.03	0.03	0.03	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Allocated Share Based Compensation Expense		3.87	4.09	4.54	5.13	5.14	4.39	4.43	4.55	3.90	3.63	3.85	3.71	3.12	3.10	2.62	2.49	2.28	1.55	1.76	0.29	0.26	NA
Profit Loss		-11.89	-25.06	-28.49	-23.95	-31.04	-28.17	-22.29	-11.28	21.66	-18.69	-23.45	-26.02	-32.70	-26.84	-20.92	-20.74	-19.44	-31.78	-15.44	-9.76	-11.83	-9.01
Net Income Loss		-11.89	-25.06	-28.49	-23.95	-31.04	-28.17	-22.29	-11.28	21.66	-18.69	-23.45	-26.02	-32.70	-26.84	-20.92	-20.74	-19.44	-31.78	-15.44	-9.76	-11.83	-9.01

		2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31
Assets		181.70	204.50	238.17	271.73	297.16	181.35	211.50	227.20	230.11	262.32	150.16	168.69	184.19	214.20	235.23	260.30	271.92	166.80	138.60	NA	NA	NA
Liabilities		147.66	164.32	177.74	187.35	194.14	111.69	120.33	125.76	129.56	203.49	105.73	104.86	98.59	99.17	96.92	104.51	97.94	155.97	98.64	NA	NA	NA
Liabilities And Stockholders Equity		181.70	204.50	238.17	271.73	297.16	181.35	211.50	227.20	230.11	262.32	150.16	168.69	184.19	214.20	235.23	260.30	271.92	166.80	138.60	NA	NA	NA
Stockholders Equity		34.04	40.18	60.43	84.38	103.02	69.66	91.17	101.44	100.55	58.82	44.42	63.82	85.60	115.03	138.31	155.79	173.98	10.83	39.96	53.59	41.11	-35.21

		2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31
Assets Current		147.86	169.02	199.10	225.37	247.69	134.05	161.75	183.05	188.30	219.14	105.56	122.56	137.39	166.84	193.67	219.50	237.09	136.98	115.67	NA	NA	NA
Cash And Cash Equivalents At Carrying Value		137.79	158.13	189.58	212.05	184.13	116.22	143.66	160.47	173.94	193.46	89.80	104.15	126.89	154.19	180.89	206.26	226.10	116.50	103.19	NA	125.34	47.75
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents		137.79	158.13	189.58	212.05	184.13	116.22	143.66	160.47	173.94	193.46	89.80	104.15	126.89	154.19	180.89	206.26	226.10	116.50	103.19	127.57	NA	NA
Accounts Receivable Net Current		0.65	0.69	0.72	0.71	50.51	0.49	0.49	0.49	0.49	19.26	10.00	10.12	0.08	3.86	0.96	0.25	0.25	6.16	0.52	NA	NA	NA
Other Assets Current		0.50	1.77	1.26	0.31	0.42	0.28	0.17	0.90	5.42	0.04	0.00	0.06	0.24	0.93	2.32	2.25	2.47	6.03	3.05	NA	NA	NA

		2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31
Property Plant And Equipment Gross		NA	NA	51.28	NA	NA	NA	49.07	NA	NA	NA	54.17	NA	NA	NA	50.22	NA	NA	NA	26.63	NA	NA	NA
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment		NA	NA	31.09	NA	NA	NA	23.91	NA	NA	NA	19.08	NA	NA	NA	10.65	NA	NA	NA	5.48	NA	NA	NA
Property Plant And Equipment Net		18.25	18.59	20.19	21.79	23.05	23.87	25.15	31.54	32.78	33.89	35.09	36.49	37.54	38.78	39.57	38.96	32.96	27.91	21.15	NA	NA	NA
Intangible Assets Net Excluding Goodwill		1.55	1.52	1.35	1.97	2.00	2.02	2.05	2.07	1.34	1.36	1.37	1.39	1.40	1.42	1.43	1.45	1.45	1.46	1.47	NA	NA	NA
Finite Lived Intangible Assets Net		NA	NA	1.35	NA	NA	NA	2.05	NA	NA	NA	1.37	NA	NA	NA	1.43	NA	NA	NA	1.47	NA	NA	NA
Other Assets Noncurrent		0.62	2.75	2.57	9.52	9.33	4.66	4.64	4.22	1.86	1.81	1.72	1.55	1.36	0.57	0.56	0.39	0.42	0.45	0.31	NA	NA	NA

		2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31
Liabilities Current		56.40	46.86	59.66	61.15	53.92	29.11	35.98	36.48	36.25	63.80	42.83	41.98	34.31	23.76	26.93	23.73	15.82	71.38	14.07	NA	NA	NA
Accounts Payable Current		0.78	0.70	1.23	1.06	0.80	0.70	1.14	0.49	0.48	0.45	0.79	0.96	1.59	1.77	2.04	4.46	2.88	5.06	2.22	NA	NA	NA
Other Liabilities Current		1.21	1.41	0.74	1.23	1.45	1.62	0.98	1.88	1.61	2.03	0.85	NA	NA	NA	1.58	NA	NA	NA	NA	NA	NA	NA
Contract With Customer Liability Current		23.81	38.27	46.19	48.41	41.51	19.69	21.24	21.98	22.22	53.09	30.24	29.22	23.06	13.31	16.49	10.77	7.13	9.47	8.44	NA	NA	NA

		2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31
Long Term Debt		NA	22.27	22.22	22.17	22.12	2.48	2.48	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Deferred Income Tax Liabilities Net		NA	NA	1.17	NA	NA	NA	1.55	NA	NA	NA	2.02	NA	NA	NA	1.46	NA	NA	NA	NA	NA	NA	NA
Other Liabilities Noncurrent		NA	0.20	0.20	0.22	0.23	0.03	0.04	0.48	0.49	0.39	0.39	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Operating Lease Liability Noncurrent		3.17	2.23	2.78	3.31	3.82	4.33	4.81	6.97	7.52	8.06	8.59	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

		2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31
Stockholders Equity		34.04	40.18	60.43	84.38	103.02	69.66	91.17	101.44	100.55	58.82	44.42	63.82	85.60	115.03	138.31	155.79	173.98	10.83	39.96	53.59	41.11	-35.21
Additional Paid In Capital Common Stock		500.25	494.50	489.70	485.15	479.85	415.45	408.80	396.78	384.61	364.54	331.45	327.40	323.15	319.89	316.33	312.89	310.34	127.75	126.09	NA	NA	NA
Retained Earnings Accumulated Deficit		-465.26	-453.37	-428.31	-399.82	-375.88	-344.84	-316.68	-294.38	-283.11	-304.76	-286.07	-262.62	-236.60	-203.90	-177.07	-156.15	-135.41	-115.97	-85.19	NA	NA	NA
Stock Issued During Period Value New Issues		1.88	0.42	NA	NA	47.67	1.65	NA	3.84	14.83	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	21.92	87.83	NA
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value		3.87	4.09	NA	5.13	5.14	4.39	NA	4.55	3.90	3.63	NA	3.71	3.12	3.10	NA	2.49	2.28	1.55	NA	0.29	0.25	0.15

		2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31
Net Cash Provided By Used In Operating Activities		-21.13	-31.46	-21.84	29.19	-24.22	-28.87	-23.68	-23.91	-31.34	68.07	-13.45	-22.22	-25.80	-25.91	-20.56	-13.98	-16.57	-19.91	-12.91	-15.05	-9.31	-14.45
Net Cash Provided By Used In Investing Activities		-1.06	-0.72	-0.63	-1.09	-0.78	-0.82	-1.50	-1.48	-1.69	-1.12	-1.10	-1.05	-1.78	-1.10	-5.53	-5.92	-8.14	-5.08	-9.87	-4.04	-1.13	-0.62
Net Cash Provided By Used In Financing Activities		1.85	0.74	0.00	-0.18	92.92	2.25	8.38	11.92	13.51	36.72	0.20	0.53	0.28	0.31	0.71	0.06	134.31	38.30	-1.59	21.32	88.03	0.02

		2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31
Net Cash Provided By Used In Operating Activities		-21.13	-31.46	-21.84	29.19	-24.22	-28.87	-23.68	-23.91	-31.34	68.07	-13.45	-22.22	-25.80	-25.91	-20.56	-13.98	-16.57	-19.91	-12.91	-15.05	-9.31	-14.45
Net Income Loss		-11.89	-25.06	-28.49	-23.95	-31.04	-28.17	-22.29	-11.28	21.66	-18.69	-23.45	-26.02	-32.70	-26.84	-20.92	-20.74	-19.44	-31.78	-15.44	-9.76	-11.83	-9.01
Profit Loss		-11.89	-25.06	-28.49	-23.95	-31.04	-28.17	-22.29	-11.28	21.66	-18.69	-23.45	-26.02	-32.70	-26.84	-20.92	-20.74	-19.44	-31.78	-15.44	-9.76	-11.83	-9.01
Increase Decrease In Accounts Receivable		-0.04	-0.03	0.01	-49.79	NA	NA	0.00	0.00	-18.77	9.26	-0.12	10.03	-3.78	2.89	0.71	0.00	-5.91	5.63	-6.00	NA	NA	NA
Increase Decrease In Accounts Payable		0.12	-0.56	0.34	0.39	-0.20	-0.37	0.63	0.05	-0.03	0.22	-0.12	-1.22	0.14	-0.27	0.07	0.39	-1.27	1.48	-1.63	0.72	-0.12	0.35
Share Based Compensation		3.87	4.09	4.54	5.13	5.14	4.39	4.43	4.55	3.90	3.63	3.85	3.71	3.12	3.10	2.62	2.49	2.28	1.55	1.76	0.29	0.26	0.15

		2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31
Net Cash Provided By Used In Investing Activities		-1.06	-0.72	-0.63	-1.09	-0.78	-0.82	-1.50	-1.48	-1.69	-1.12	-1.10	-1.05	-1.78	-1.10	-5.53	-5.92	-8.14	-5.08	-9.87	-4.04	-1.13	-0.62
Payments To Acquire Productive Assets		1.08	0.52	0.63	1.09	0.78	0.82	1.50	0.73	1.69	1.12	1.10	1.05	1.78	1.10	5.53	5.92	8.14	5.08	9.87	2.66	1.13	0.62

		2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31
Net Cash Provided By Used In Financing Activities		1.85	0.74	0.00	-0.18	92.92	2.25	8.38	11.92	13.51	36.72	0.20	0.53	0.28	0.31	0.71	0.06	134.31	38.30	-1.59	21.32	88.03	0.02

		2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31
Revenues		19.79	8.78	10.60	7.36	3.82	3.32	6.34	24.04	68.81	16.35	8.85	7.36	1.08	7.00	6.52	4.87	5.39	5.46	4.94	2.54	1.87	1.53
Eli Lilly And Company, Research And Development Arrangement		NA	2.90	4.70	3.80	3.80	3.30	5.40	4.90	5.30	5.40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Novartis Pharma A G, Research And Development Arrangement		4.80	5.90	5.90	3.60	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Prevail Therapeutics Inc, Research And Development Arrangement		15.00	NA	NA	NA	3.80	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Revenue From Contract With Customer Excluding Assessed Tax		19.79	8.78	10.60	7.36	3.82	3.32	6.34	24.04	68.81	16.35	8.85	7.36	1.08	7.00	6.52	4.87	5.39	5.46	4.94	2.54	1.87	1.53
Eli Lilly And Company, Research And Development Arrangement		NA	2.90	4.70	3.80	3.80	3.30	5.40	4.90	5.30	5.40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Novartis Pharma A G, Research And Development Arrangement		4.80	5.90	5.90	3.60	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Prevail Therapeutics Inc, Research And Development Arrangement		15.00	NA	NA	NA	3.80	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

Plots across concepts

Line plots across dimensions of each concept